Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors.

Oncotarget 2017 12 9;8(62):105103-105114. Epub 2017 Oct 9.

CHU Lille, Thoracic Oncology Department, Univ. Lille, Siric ONCOLille, Lille, France.

Background: Several mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutated NSCLC have been described including the T790M mutation and amplification. Whereas T790M mutation confers prolonged survival and sensitivity to 3rd generation TKIs, data are lacking on clinical features and outcome of MET-driven resistant EGFR-mutated NSCLC patients.

Methods: Patients with metastatic EGFR-mutated NSCLC displaying high MET overexpression or amplification, detected on a biopsy performed after progression on EGFR TKI, were identified in 15 centers. Clinical and molecular data were retrospectively collected.

Results: Forty two patients were included. The median overall survival (OS), and the median post EGFR TKI progression overall survival (PPOS) were 36.2 months [95%CI 27.3-66.5] and 18.5 months [95%CI 10.6-27.4] respectively. Nineteen out of 36 tumors tested for MET FISH had amplification. A T790M mutation was found in 11/41 (26.8%) patients. T790M-positive patients had a better OS than T790M-negative patients (p=0.0224). Nineteen patients received a MET TKI. Objective response was reported in 1 out of 12 evaluable patients treated with a MET inhibitor as a single agent and in 1 of 2 patients treated with a combination of MET and EGFR TKIs.

Conclusion: MET-driven resistance to EGFR TKI defines a specific pattern of resistance characterized by low objective response rate to MET inhibitors given alone and overlapping with T790M mutations. Further studies are warranted to define adequate therapeutic strategies for MET-driven resistance to EGFR TKI.

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.21707DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739624PMC
December 2017
26 Reads

Publication Analysis

Top Keywords

resistance egfr
16
egfr-mutated nsclc
16
egfr tki
16
t790m mutation
12
met-driven resistance
12
patients
9
kinase inhibitors
8
tyrosine kinase
8
patients treated
8
months [95%ci
8
egfr tyrosine
8
amplification t790m
8
objective response
8
egfr
7
met
6
resistance
5
tki
5
106-274] nineteen
4
nineteen tumors
4
tumors tested
4

Similar Publications